Windtree raises $250K via secured notes, licenses Phexxi supply rights, regains Nasdaq compliance

WINDTREE THERAPEUTICS INC /DE/

Issued $312,500 principal in senior secured notes at 10% interest, due March 2026, with 20% OID; net proceeds $250,000.
Entered license and supply agreement with Evofem to manufacture and supply Phexxi outside the U.S. for an initial three-year term.
Regained compliance with Nasdaq minimum bid price rule (closing bid >$1.00 since Feb 21, 2025); subject to panel monitor until March 20, 2026.
Notes secured by first-priority lien on all assets; mandatory redemption of 30% of equity line proceeds if equity line is used.

item 1.01 item 2.03 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.